Literature DB >> 31184438

Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity.

Pierluigi Marzuillo1, Anna Di Sessa1, Stefano Guarino1, Daniela Capalbo1, Giuseppina Rosaria Umano1, Marcella Pedullà1, Angela La Manna1, Grazia Cirillo1, Emanuele Miraglia Del Giudice1.   

Abstract

BACKGROUND: PNPLA3 I148M polymorphism has an effect on modulation of estimated glomerular filtration rate (eGFR) in nonobese nondiabetic adults and in children with histologically confirmed nonalcoholic fatty liver disease (NAFLD).
OBJECTIVES: The objective of the study is to explore the impact of PNPLA3 I148M polymorphism on eGFR in children with obesity with and without NAFLD.
METHODS: We genotyped 591 patients with obesity for PNPLA3 I148M polymorphism. Anthropometrical, biochemical, and instrumental data were collected. NAFLD was defined by the presence of ultrasound-detected liver steatosis and/or ALT levels greater than 40 IU/L.
RESULTS: Patients with NAFLD showed significantly lower eGFR levels compared with subjects without NAFLD. Children with PNPLA3 MM genotype showed lower eGFR levels compared with those with either PNPLA3 IM or II genotypes both in the presence and absence of NAFLD. A general linear model for eGFR variance, including gender, duration of obesity, PNPLA3 genotypes, HOMA, BMI-SDS, LDL-C, and triglycerides as covariates, confirmed an inverse association between eGFR and PNPLA3 genotype only in the presence of NAFLD.
CONCLUSIONS: Children with obesity and PNPLA3 MM genotype show lower eGFR levels compared with other genotypes, with a major effect of this polymorphism in the presence of NAFLD.
© 2019 World Obesity Federation.

Entities:  

Keywords:  NAFLD; PNPLA3; children; chronic kidney disease; obesity; renal function

Mesh:

Substances:

Year:  2019        PMID: 31184438     DOI: 10.1111/ijpo.12539

Source DB:  PubMed          Journal:  Pediatr Obes        ISSN: 2047-6302            Impact factor:   4.000


  13 in total

Review 1.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

Review 2.  Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.

Authors:  Simona Riccio; Rosa Melone; Caterina Vitulano; Pierfrancesco Guida; Ivan Maddaluno; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Clin Pediatr       Date:  2022-03-23

Review 3.  Perspectives on youth-onset nonalcoholic fatty liver disease.

Authors:  Eduardo Castillo-Leon; Catherine E Cioffi; Miriam B Vos
Journal:  Endocrinol Diabetes Metab       Date:  2020-09-17

4.  Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management.

Authors:  Anna Di Sessa; Grazia Cirillo; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice
Journal:  Pediatric Health Med Ther       Date:  2019-08-23

Review 5.  New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease.

Authors:  Yu-Cheng Lin; Chi-Chien Wu; Yen-Hsuan Ni
Journal:  Front Pediatr       Date:  2020-12-09       Impact factor: 3.418

Review 6.  Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes.

Authors:  Alessandro Mantovani; Andrea Dalbeni; Giorgia Beatrice; Davide Cappelli; Fernando Gomez-Peralta
Journal:  J Clin Med       Date:  2022-02-12       Impact factor: 4.241

7.  Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children.

Authors:  Alessia Di Costanzo; Lucia Pacifico; Laura D'Erasmo; Luca Polito; Michele Di Martino; Francesco Massimo Perla; Ludovica Iezzi; Claudio Chiesa; Marcello Arca
Journal:  Int J Mol Sci       Date:  2019-09-09       Impact factor: 5.923

8.  Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant.

Authors:  Anna Di Sessa; Giuseppina Rosaria Umano; Grazia Cirillo; Antonio Paride Passaro; Valentina Verde; Domenico Cozzolino; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice
Journal:  World J Gastroenterol       Date:  2020-09-28       Impact factor: 5.742

9.  MAFLD in Obese Children: A Challenging Definition.

Authors:  Anna Di Sessa; Stefano Guarino; Giuseppina Rosaria Umano; Mattia Arenella; Salvatore Alfiero; Gaetano Quaranta; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  Children (Basel)       Date:  2021-03-23

Review 10.  Omics era in type 2 diabetes: From childhood to adulthood.

Authors:  Antonio Paride Passaro; Pierluigi Marzuillo; Stefano Guarino; Federica Scaglione; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Diabetes       Date:  2021-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.